Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 placebo-controlled dose-ranging trial of thalidomide in transfusion-dependent beta-thalassemia
ChiCTR2200066232Phase 2Not yet recruiting
- Sponsor
- Wuzhou Workers' Hospital
- Start
- Dec 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of thalidomide in beta thalassemia (4 arms), sponsored by Wuzhou Workers' Hospital. Primary endpoints: Hemoglobin and Volume of blood transfusion. Planned start Dec 2022; status: not yet recruiting.
02
Drugs
thalidomide
03
Conditions
beta thalassemia
Beyond the preview
Go deeper on ChiCTR2200066232.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200066232.